原発性胆汁性胆管炎の世界市場レポート 2024

原発性胆汁性胆管炎の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.4%の年間複合成長率（CAGR）で14億6,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、バイオマーカー調査の拡大、希少疾患管理における世界の取り組み、臨床試験における連携の強化、患者中心のヘルスケア戦略、肝移植の需要の増加に関連しています。予測期間中に予想される主な動向には、バイオマーカー調査の進歩、非侵襲的診断アプローチの重視の高まり、免疫調節療法への調査集中、人工知能（AI）の組み込み、臨床試験における患者報告結果の組み込み、患者管理のための遠隔医療の利用、併用療法への注目、線維症を標的とした治療法の出現などです。

予想される喫煙者の増加により、今後数年間で原発性胆汁性胆管炎市場の拡大が促進されると見込まれています。喫煙には、タバコやその他の物質を燃やすことによって発生する煙の吸入と吐き出しが含まれます。これはPBCを含む肝疾患の危険因子として認識されており、喫煙率の上昇により、肝臓関連の問題で医療機関を受診する人の数が増加する可能性があります。一例として、2023年7月にカナダ統計局は、紙巻タバコ生産量が2023年6月比2.2%増加し、それに対応して紙巻タバコ販売量も2.6%増加し、6月には5月比で14億本に達したと報告しました。その結果、喫煙者の増加が原発性胆汁性胆管炎市場の成長を促進すると予想されます。

肝臓がんの急増により、近い将来、原発性胆汁性胆管炎市場の成長が促進されると予想されます。肝臓細胞に発生するがんの一種である肝臓がんは、胆管がんや肝細胞がんなどのさまざまな悪性腫瘍のリスクが高まるため、原発性胆汁性胆管炎の文脈において重要な意味を持ちます。この病気の有病率の増加とその潜在的な合併症は、原発性胆汁性胆管炎市場の拡大に貢献しています。たとえば、国立バイオテクノロジー情報センターは2022年 10月に、2020年から2040年の間に肝臓がんの発生率が55.0%増加し、死亡者数が56.4%増加するとの予測を報告しました。したがって、肝臓がんの急増が原発性胆汁性胆管炎市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の原発性胆汁性胆管炎市場、治療タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 薬物
• 肝移植
• 世界の原発性胆汁性胆管炎市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 画像検査
• 磁気共鳴エラストグラフィー（MRE）
• 磁気共鳴胆管膵管造影（MRCP）
• 超音波
• フィブロスキャン
• 血液検査
• コレステロール検査
• 抗体検査
• 肝臓検査
• その他の診断
• 世界の原発性胆汁性胆管炎市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• 在宅ケア
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の原発性胆汁性胆管炎市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の原発性胆汁性胆管炎市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原発性胆汁性胆管炎市場の競合情勢
• 原発性胆汁性胆管炎市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck And Co. Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company

第31章 その他の主要および革新的な企業

• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• Gilead Sciences Inc.
• Vertex Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Intercept Pharmaceuticals Inc
• Arrowhead Pharmaceuticals Inc.
• CureVac NV
• Sangamo Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

The main types of treatment for primary biliary cholangitis are drugs and liver transplantation. A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed, and ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC. UDCA helps improve liver function, reduce liver inflammation, and slow down disease progression. Primary biliary cholangitis is diagnosed through various imaging tests such as magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, as well as blood tests including cholesterol tests, antibody tests, and liver function tests. These diagnostic methods are employed by end-users such as specialty clinics, homecare services, and other healthcare facilities.

The primary biliary cholangitis market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis market statistics, including primary biliary cholangitis industry global market size, regional shares, competitors with a primary biliary cholangitis market share, detailed primary biliary cholangitis market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. This primary biliary cholangitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary biliary cholangitis market size has grown rapidly in recent years. It will grow from $0.87 billion in 2023 to $0.98 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth observed in the historical period can be attributed to various factors, including increased disease awareness, a rise in global healthcare expenditure, strategic collaborations in the healthcare sector, a focus on patient advocacy, and government initiatives for liver health. These factors have collectively contributed to the growth and development of approaches for addressing primary biliary cholangitis (PBC) during the historic period.

The primary biliary cholangitis market size is expected to see rapid growth in the next few years. It will grow to $1.46 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth during the forecast period is linked to the expansion of biomarker research, worldwide initiatives in managing rare diseases, heightened collaboration in clinical trials, patient-centric healthcare strategies, and an increased demand for liver transplants. Key trends expected in the forecast period encompass progress in biomarker research, an escalating emphasis on non-invasive diagnostic approaches, research concentration on immunomodulatory therapies, the incorporation of artificial intelligence (AI), the inclusion of patient-reported outcomes in clinical trials, the utilization of telemedicine for patient management, a focus on combination therapies, and the emergence of therapies targeting fibrosis.

The anticipated rise in smoking is poised to drive the expansion of the primary biliary cholangitis market in the coming years. Smoking involves the inhalation and exhalation of smoke generated by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and elevated smoking rates may result in an increased number of individuals seeking medical attention for liver-related issues. As an illustration, in July 2023, Statistics Canada reported a 2.2% increase in cigarette production compared to June 2023, with a corresponding 2.6% rise in cigarette sales, reaching 1.4 billion units in June compared to May. Consequently, the upswing in smoking is expected to propel the primary biliary cholangitis market's growth.

The upsurge in liver cancer is anticipated to foster the growth of the primary biliary cholangitis market in the foreseeable future. Liver cancer, a type of cancer originating in the liver cells, holds significance in the context of primary biliary cholangitis due to the heightened risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The increasing prevalence of the disease and its potential complications contribute to the expansion of the primary biliary cholangitis market. For instance, in October 2022, the National Center for Biotechnology Information reported a projected 55.0% increase in the incidence of liver cancer and a 56.4% rise in the number of deaths between 2020 and 2040. Hence, the surge in liver cancer is a driving force behind the growth of the primary biliary cholangitis market.

The anticipated shortage of skilled healthcare professionals is poised to impede the growth of the primary biliary cholangitis market in the future. The scarcity of qualified healthcare professionals results in delayed diagnosis and treatment, hindering the effective management and monitoring of PBC patients. Moreover, the shortage of skilled healthcare professionals acts as a bottleneck in the progress towards discovering new and more effective therapies for PBC. As an example, in June 2022, the World Health Organization reported a global healthcare workforce shortage of 15 million in 2022. Consequently, the insufficiency of skilled healthcare professionals is a limiting factor in the growth of the primary biliary cholangitis market.

Major companies operating in the primary biliary cholangitis market are directing their efforts towards the development of innovative and specialized treatments. This includes the creation of orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), aiming to secure market exclusivity. The combination of OCA and bezafibrate, with an orphan drug designation, seeks to provide a more comprehensive and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate as a potential treatment for PBC, a progressive liver disease, with OCA already approved for PBC in the US.

In March 2023, Ipsen SA, a France-based pharmaceutical company, completed the acquisition of Albireo Pharma, Inc. for an undisclosed amount. This strategic move by Ipsen aims to broaden its rare disease portfolio by incorporating novel pipeline prospects, promising therapies for rare cholestatic liver diseases in both children and adults, and leveraging strong scientific and commercial capabilities. Albireo Pharma Inc., a US-based biopharmaceutical company, is actively developing A3907 therapy for primary biliary cholangitis (PBC), contributing to Ipsen's expansion in the rare disease segment.

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc, TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

North America was the largest region in the primary biliary cholangitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary biliary cholangitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Biliary Cholangitis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary biliary cholangitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary biliary cholangitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment Type: Drugs; Liver Transplantation
• 2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
• 3) By End-Users: Specialty Clinics; Homecare; Other End-Users
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Biliary Cholangitis Market Characteristics

3. Primary Biliary Cholangitis Market Trends And Strategies

4. Primary Biliary Cholangitis Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Primary Biliary Cholangitis Market Size and Growth

• 5.1. Global Primary Biliary Cholangitis Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Primary Biliary Cholangitis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Primary Biliary Cholangitis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Primary Biliary Cholangitis Market Segmentation

• 6.1. Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Drugs
• Liver Transplantation
• 6.2. Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Imaging Tests
• Magnetic Resonance Elastography (MRE)
• Magnetic Resonance Cholangiopancreatography (MRCP)
• Ultrasound
• Fibroscan
• Blood Tests
• Cholesterol Test
• Antibody Tests
• Liver Tests
• Other Diagnoses
• 6.3. Global Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users

7. Primary Biliary Cholangitis Market Regional And Country Analysis

• 7.1. Global Primary Biliary Cholangitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Primary Biliary Cholangitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Primary Biliary Cholangitis Market

• 8.1. Asia-Pacific Primary Biliary Cholangitis Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Primary Biliary Cholangitis Market

• 9.1. China Primary Biliary Cholangitis Market Overview
• 9.2. China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Primary Biliary Cholangitis Market

• 10.1. India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Primary Biliary Cholangitis Market

• 11.1. Japan Primary Biliary Cholangitis Market Overview
• 11.2. Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Primary Biliary Cholangitis Market

• 12.1. Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Primary Biliary Cholangitis Market

• 13.1. Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Primary Biliary Cholangitis Market

• 14.1. South Korea Primary Biliary Cholangitis Market Overview
• 14.2. South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Primary Biliary Cholangitis Market

• 15.1. Western Europe Primary Biliary Cholangitis Market Overview
• 15.2. Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Primary Biliary Cholangitis Market

• 16.1. UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Primary Biliary Cholangitis Market

• 17.1. Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Primary Biliary Cholangitis Market

• 18.1. France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Primary Biliary Cholangitis Market

• 19.1. Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Primary Biliary Cholangitis Market

• 20.1. Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Primary Biliary Cholangitis Market

• 21.1. Eastern Europe Primary Biliary Cholangitis Market Overview
• 21.2. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Primary Biliary Cholangitis Market

• 22.1. Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Primary Biliary Cholangitis Market

• 23.1. North America Primary Biliary Cholangitis Market Overview
• 23.2. North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Primary Biliary Cholangitis Market

• 24.1. USA Primary Biliary Cholangitis Market Overview
• 24.2. USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Primary Biliary Cholangitis Market

• 25.1. Canada Primary Biliary Cholangitis Market Overview
• 25.2. Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Primary Biliary Cholangitis Market

• 26.1. South America Primary Biliary Cholangitis Market Overview
• 26.2. South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Primary Biliary Cholangitis Market

• 27.1. Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Primary Biliary Cholangitis Market

• 28.1. Middle East Primary Biliary Cholangitis Market Overview
• 28.2. Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Primary Biliary Cholangitis Market

• 29.1. Africa Primary Biliary Cholangitis Market Overview
• 29.2. Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Primary Biliary Cholangitis Market Competitive Landscape And Company Profiles

• 30.1. Primary Biliary Cholangitis Market Competitive Landscape
• 30.2. Primary Biliary Cholangitis Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck And Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol-Myers Squibb Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Primary Biliary Cholangitis Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH.
• 31.6. Gilead Sciences Inc.
• 31.7. Vertex Pharmaceuticals
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Amneal Pharmaceuticals LLC
• 31.10. Alnylam Pharmaceuticals Inc.
• 31.11. Ionis Pharmaceuticals Inc.
• 31.12. Intercept Pharmaceuticals Inc
• 31.13. Arrowhead Pharmaceuticals Inc.
• 31.14. CureVac N.V.
• 31.15. Sangamo Therapeutics Inc.

32. Global Primary Biliary Cholangitis Market Competitive Benchmarking

33. Global Primary Biliary Cholangitis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Market

35. Primary Biliary Cholangitis Market Future Outlook and Potential Analysis

• 35.1 Primary Biliary Cholangitis Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Primary Biliary Cholangitis Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Primary Biliary Cholangitis Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer